New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
06:05 EDTPSTIPluristem's commercial scale cell manufacturing process approved by FDA
Pluristem Therapeutics announced that the FDA has reviewed Pluristem's comparability studies of its PLacental eXpanded, or PLX, cell products and granted approval for the company to manufacture these products in its new commercial-scale cell manufacturing facility. Pluristem has implemented its proprietary, fully automated 3D cell expansion manufacturing platform that uses its patented high-throughput culturing technologies, 3D bioreactors, and downstream equipment. Pluristem's facility has the ability to efficiently produce approximately 150,000 doses of PLX cells annually, with batch-to-batch consistency, which potentially translates into significant economic value.
News For PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 25, 2015
18:48 EDTPSTIPluristem issues shareholder letter, sees submitting PLX-R18 protocol late 2015
Subscribe for More Information
May 18, 2015
09:25 EDTPSTIOn The Fly: Pre-market Movers
Subscribe for More Information
05:13 EDTPSTIPluristem PLX Cells selected for EMA adaptive pathways pilot project
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use